A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
10/2004
10/28/2004	WO2004091527A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
10/28/2004	WO2004091526A2 Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies
10/28/2004	WO2004091525A2 Morpholino imaging and therapy via amplification targeting
10/28/2004	WO2004091524A2 Respiratory virus vaccines
10/28/2004	WO2004091523A2 Method for identifying ligands specific for structural isoforms of proteins
10/28/2004	WO2004091522A2 Method for treating neurodegenerative disorders
10/28/2004	WO2004091521A2 Methods and compositions for administration of trpv1 agonists
10/28/2004	WO2004091520A2 Methods and compositions for treating atherosclerosis
10/28/2004	WO2004091519A2 Methods of preventing or treating respiratory conditions
10/28/2004	WO2004091517A2 Conjugates comprising human il-18 and substitution mutants thereof
10/28/2004	WO2004091516A2 Methods for controlling the proliferation of cells
10/28/2004	WO2004091515A2 iRNA CONJUGATES
10/28/2004	WO2004091514A2 Cgrp receptor antagonists
10/28/2004	WO2004091513A2 9-aminomethyl substituted minocycline compounds
10/28/2004	WO2004091512A2 Abuse-resistant oral dosage forms and method of use thereof
10/28/2004	WO2004091511A2 Compositions and methods to diagnose and treat lung cancer
10/28/2004	WO2004091509A2 Interlinked culture chambers for biologicals
10/28/2004	WO2004091508A2 Fullerene compositions for ameliorating dermatological conditions
10/28/2004	WO2004091507A2 Optimal polyvalent vaccine for cancer
10/28/2004	WO2004091506A2 Taxane-based compositions and methods of use
10/28/2004	WO2004091505A2 Bacteriophage for lysis of methylobacterium and compositions and uses thereof
10/28/2004	WO2004091504A2 Substituted quinobenzoxazine analogs
10/28/2004	WO2004091503A2 Systems and methods for respiratory event detection
10/28/2004	WO2004091500A2 Delivery of immune response modifier compounds
10/28/2004	WO2004091499A2 Intracellular formation of peptide conjugates
10/28/2004	WO2004091497A2 Methods and compositions for increasing the anaerobic working capacity in tissues
10/28/2004	WO2004091495A2 Compositions and methods related to production of erythropoietin
10/28/2004	WO2004091494A2 Method for preparation of site-specific protein conjugates
10/28/2004	WO2004091493A2 Improved heat shock protein-based vaccines and immunotherapies
10/28/2004	WO2004091491A2 Profiling conformational variants, antibody compositions and methods of using the same
10/28/2004	WO2004091490A2 Somatostatin-dopamine chimeric analogs
10/28/2004	WO2004091488A2 Estrogen receptor modulators
10/28/2004	WO2004091487A2 Hemophilia treatment by inhalation of coagulation factors
10/28/2004	WO2004091486A2 Compounds for the treatment of metabolic disorders
10/28/2004	WO2004091484A2 Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
10/28/2004	WO2004091483A2 Once daily formulations of tetracyclines
10/28/2004	WO2004091482A2 M3 muscarinic acetylcholine receptor antagonists
10/28/2004	WO2004091480A2 Tie-2 modulators and methods of use
10/28/2004	WO2004091479A2 Gene amplification and overexpression in cancer
10/28/2004	WO2004091476A2 Method of screening remedy for heart disease and medicinal composition for treating heart disease
10/28/2004	WO2004091475A2 Gaucher disease drugs and methods of identifying same
10/28/2004	WO2004078111A3 Extended release minocycline compositions and processes for their preparation
10/28/2004	WO2004073655A9 Radiation phantom
10/28/2004	WO2004073612A3 Estrogen receptor modulators
10/28/2004	WO2004071442A3 Novel bicyclic compounds and compositions
10/28/2004	WO2004071438A3 Cosmetic compositions containing phenyl silicones
10/28/2004	WO2004069205A3 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
10/28/2004	WO2004069167A3 Method and compositions for treating male infertility
10/28/2004	WO2004062615A3 Tactile agents
10/28/2004	WO2004062560A3 Pharmaceutical composition
10/28/2004	WO2004043386A3 Molecules preferentially associated with effector t cells and methods of their use
10/28/2004	WO2004041188A3 Compositions and methods for transdermal oxybutynin therapy
10/28/2004	WO2004037205A3 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
10/28/2004	WO2004032867A3 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
10/28/2004	WO2004024075A3 Chemokine receptor antagonists as therapeutic agents
10/28/2004	WO2004014318A3 Levothyroxine compositions and methods
10/28/2004	WO2003099229A3 Functional protein expression for rapid cell-free phenotyping
10/28/2004	US20040214843 Such as spiro(cyclohexane-1-4'-(3',4'-dihydro)quinazolin)-2'(1'H)-one for treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, asthma and cancer
10/28/2004	US20040214841 Quinazoline derivatives for treatment of tumours
10/28/2004	US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
10/28/2004	US20040214814 Pyrazole compounds useful as protein kinase inhibitors
10/28/2004	US20040214802 Dipyridamole, acetylsalicylic acid, and angiotensin II antagonist pharmaceutical compositions
10/28/2004	US20040214793 In aitu applying to bone joints
10/28/2004	US20040214782 caused by infection from Eimeria bovis, Eimeria zuernii or E. aubernensis; administering macrolide antibiotics, azalide class, such as tilmicosin
10/28/2004	US20040214771 Cleaved serum response factor in cardiac diagnosis and therapy
10/28/2004	US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist
10/28/2004	US20040214317 Nucleotide sequences coding membrane protein for use in treatment and prevention of anxiolytic, brain and nervous system disorders
10/28/2004	US20040214297 Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
10/28/2004	US20040214239 Functional coupling of T1Rs and T2Rs by GI proteins, and cell-based assays for the identification of T1R and T2R modulators
10/28/2004	US20040214236 Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
10/28/2004	US20040213832 non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at a rate and in an amount sufficient to induce and maintain analgesia over a period of at least three days, and up to 7 days to a patient in need thereof
10/28/2004	US20040213808 immunogenic compositions containing as active ingredients recombinantly-produced forms of truncated flavivirus envelope and non-structural glycoproteins; may also include an adjuvant, such as saponin or a saponin-like material
10/28/2004	US20040213800 Active immunization to generate antibodies to soluble A-beta
10/28/2004	US20040213783 modulation of CD200 or CD200R using a polyclonal antibody; a monoclonal antibody; a humanized antibody; an Fv, Fab, or F(ab')2 fragment; a blocking antibody; or a peptide mimetic of an antibody; autoimmune disorders
10/28/2004	US20040213782 Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
10/28/2004	US20040213761 administering to a patient an effective amount of an agonist or antagonist of IL-23, for wound healing
10/28/2004	US20040213264 Service class and destination dominance traffic management
10/28/2004	CA2809764A1 Systems and methods for respiratory event detection
10/28/2004	CA2803922A1 Once daily formulations of tetracyclines
10/28/2004	CA2523693A1 Bacteriophage for lysis of methylobacterium and compositions and uses thereof
10/28/2004	CA2522483A1 Method for identifying ligands specific for structural isoforms of proteins
10/28/2004	CA2522299A1 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
10/28/2004	CA2522298A1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom
10/28/2004	CA2522297A1 Process for making gel films
10/28/2004	CA2522296A1 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
10/28/2004	CA2522293A1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
10/28/2004	CA2522080A1 N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
10/28/2004	CA2522007A1 Methods of preventing or treating respiratory conditions
10/28/2004	CA2522006A1 Systems and methods for respiratory event detection
10/28/2004	CA2521987A1 Methods and compositions for increasing the anaerobic working capacity in tissues
10/28/2004	CA2521979A1 Compositions and methods related to production of erythropoietin
10/28/2004	CA2521965A1 Somatostatin-dopamine chimeric analogs
10/28/2004	CA2521818A1 Fullerene compositions for ameliorating dermatological conditions
10/28/2004	CA2521812A1 Optimal polyvalent vaccine for cancer
10/28/2004	CA2521810A1 Substituted quinobenzoxazine analogs
10/28/2004	CA2521809A1 Improved heat shock protein-based vaccines and immunotherapies
10/28/2004	CA2521655A1 Abuse-resistant oral dosage forms and method of use thereof
10/28/2004	CA2521471A1 Methods of administering estrogens and progestins
10/28/2004	CA2521464A1 Irna conjugates
10/28/2004	CA2521381A1 Method for preparation of site-specific protein conjugates

1 ... 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 ... 295